Samsung BioLogics to Manufacture Tildrakizumab

Sun Pharma and Samsung BioLogics announced on July 4, 2017 a strategic long-term manufacturing agreement that Samsung Biologics will manufacture tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis. The approximate value of the contract will be $55.5 million, the companies reported in a press announcement.

Filings for the novel investigational biologic was accepted for review by FDA in May 2017) and the European Medicines Agency in March 2017.

“Samsung BioLogics is pleased to join hands with Sun Pharma and is looking forward to delivering best-in-class manufacturing services with global quality standards,” said TH Kim, President and CEO of Samsung BioLogics in the statement. “Our collaboration with Sun Pharma is an important milestone for Samsung as it is a testament of our ability to provide reliable supply through its GMP-certified manufacturing facility to pharmaceutical companies, which aim to expand their global market.”

“Samsung BioLogics is a globally renowned CMO. Through this partnership we will leverage Samsung’s manufacturing knowledge and world class quality systems to provide high quality products for the tildrakizumab pipeline,” said Kirti Ganorkar, Global Head – Portfolio Management & Business Development, Sun Pharma.

Source: Samsung Biologics